Drugs / YF Vax 17D Strain
Trials 0
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02963909 Background | Nov 2016 → Oct 2018 | Zika virus infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT02743455 Comparator | Jul 2016 → Mar 2018 | yellow fever | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | YF Vax 17D Strain | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02963909 ↗ |
| Known as | YF-VAX | “Yellow Fever Vaccine (YF-VAX) is a vaccine prepared by culturing the 17D-204 strain of yellow fever virus in living avian leucosis virus-free (ALV-free) chicken embryos.” NCT02743455 ↗1“single dose of subcutaneous yellow fever virus vaccine (YF-VAX)” PMID 37390836 ↗ Jun 2023 |
| Modality | Vaccine | “Yellow Fever Vaccine (YF-VAX) is a vaccine prepared by culturing the 17D-204 strain of yellow fever virus” NCT02743455 ↗ |
| Route | Subcutaneous | “as a single dose subcutaneously on Day 1 and matching placebo on Day 29” NCT02743455 ↗ |